At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 114 enrolled
Drug / intervention
Fondaparinux Sodium (Arixtra)drug
Likely dose
Fondaparinux Sodium (Arixtra) 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty
In Brief
A Phase 4 clinical trial evaluating Fondaparinux Sodium (Arixtra) for Total Knee Replacement. Completed, enrolled 114 participants across 1 site.
Detailed Summary
The investigators hypothesize that Arixtra patients will be less likely to experience wound infection than patients who have received low-molecular weight heparin, coumadin or aspirin with mechanical compression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTotal Knee Replacement
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartJun 2009
Primary CompletionDec 2009
TodayJul 2026
First PostedMay 27, 2009
Enrollment StartJun 1, 2009
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.1 years ago
Interventions
Fondaparinux Sodium (Arixtra)drug
2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.